SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Market Cap	$24.33M	P/E Ratio	N/A
52W High	$1.49	52W Low	$0.57
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	29.4%	52W Position	12.4%
Overall Score	63	Value Score	60
Quality Score	--	Technical Score	66

EPS Current Est	$-0.2	EPS Next Est	$1.03
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SCYX	$0.68	-1.45%	1.02M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SCYX	$0.68	-1.4%	1.02M
3
4
5
6

SCYX

SCYX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get SCYNEXIS Inc. Data in Excel

Get SCYNEXIS Inc. Data in Excel